A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma. The names of the treatment interventions involved in this study are: * Glofitamab (T-cell bispecific antibody) * Polatuzumab (antibody-drug conjugate) * R-CHP (a chemotherapy regimen comprised of Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, and Prednisone)

Trial Details

NCT ID
NCT05800366
Phase
PHASE2
Sponsor
Jennifer Crombie, MD
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Glofitamab
  • Polatuzumab
  • Rituximab
  • Doxorubicin Hydrochloride
  • Cyclophosphamide
  • Prednisone
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Previously untreated patients with CD20-positive DLBCL, including one of the following diagnoses by 2016 WHO classification of lymphoid neoplasms
  • DLBCL, not otherwise specified (NOS)
  • T-cell/histiocyte-rich large B-cell lymphoma
  • Epstein-Barr virus-positive DLBCL, NOS

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →